In vitro activity of BAY 12-8039, a new 8-methoxyquinolone

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• The emergence of antibiotic resistance necessitates the development of new antimicrobial agents.
• Quinolones are a class of synthetic broad-spectrum antibacterial drugs.

Purpose of the Study:

• To evaluate the in vitro antibacterial activity and resistance development of a new 8-methoxyquinolone, BAY 12-8039.
• To compare BAY 12-8039 with established antibiotics like ciprofloxacin, sparfloxacin, and metronidazole.

Main Methods:

• Determination of minimal inhibitory concentrations (MICs) against various Gram-positive and Gram-negative bacteria, including resistant strains.
• Assessment of spontaneous mutation frequencies to evaluate resistance development.
• Comparison of bactericidal activity with other antimicrobial agents.

Main Results:

• BAY 12-8039 exhibited significantly better activity than sparfloxacin and ciprofloxacin against methicillin-susceptible and resistant Staphylococcus aureus and Staphylococcus epidermidis.
• Potent activity was observed against Streptococcus pneumoniae, Streptococcus pyogenes, and Streptococcus agalactiae.
• Comparable activity to ciprofloxacin against most Gram-negative bacteria, except Pseudomonas aeruginosa, and similar efficacy to metronidazole against anaerobes.
• Concentration-dependent bactericidal activity and less pronounced resistance development compared to ciprofloxacin.

Conclusions:

• BAY 12-8039 demonstrates broad-spectrum antibacterial activity, particularly against Gram-positive pathogens, including resistant strains.
• Its favorable resistance profile suggests potential as a valuable therapeutic agent.